Market Overview:
The global C5a anaphylatoxin chemotactic receptor 1 market is expected to register a CAGR of xx% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in the field of medical devices. However, high cost associated with treatment and lack of awareness about available treatments may restrain the growth of this market during the forecast period. Based on type, the global C5a anaphylatoxin chemotactic receptor 1 market is segmented into EP-67, NOXD-19, NOXD-20 DF-2593A and others. Based on application, it is segmented into acute pain allergic asthma Huntington disease kidney disease and others. Geographically it has been analyzed across North America Latin America Europe Asia Pacific Middle East & Africa (MEA).
Product Definition:
C5a Anaphylatoxin Chemotactic Receptor 1 is a receptor protein that binds C5a, an anaphylatoxin that attracts white blood cells to the site of an infection or injury.
EP-67:
The global EP-67, it's usage and growth factor in C5a anaphylatoxin Chemotactic Receptor 1 market size was valued at USD 3.6 million in 2016 and is expected to grow at a compound annual growth rate (CAGR) of 8.2% from 2017 to 2022.
NOXD-19:
NOXD-19 is a novel, non-cross reactive immunosorbent assay (ICRISAT)-based test for the detection of SARS-CoV2 infection. It was developed by researchers at the University of North Texas Health Science Center in collaboration with UNT Health Foundation and has been published in the Journal of Clinical Microbiology.
Application Insights:
The acute pain segment dominated the global market in 2017. The segment is expected to witness a lucrative CAGR of XX% over the forecast period owing to an increase in chronic pain and rising number of drug eruptions associated with it. Acute pain is further classified into neurogenic, arthritic, cancer, and burns Pain based on mechanism of action includes both nocioceptive and noxious stimuli that result in unpleasant feelings which are subsequently modulated by various brain centers leading to changes in perception, behavior & consciousness (nociception). Anaphylatoxins interact with C5a receptor resulting in activation of intracellular signaling pathways such as nuclear factor Žº-B signaling pathway which eventually results in synthesis & release of inflammatory mediators from cells including macrophages & neutrophils thus resulting into inflammation at a molecular level.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of pharmaceutical and biopharmaceutical companies, advanced healthcare infrastructure, favorable reimbursement policies for new therapies development are some factors attributing to its largest share. In addition, increasing government initiatives to control anaphylaxis emergency services are also expected to drive the C5a anaphylatoxin chemotactic receptor market over the forecast period.
Asia Pacific is anticipated to grow at a lucrative rate during the forecast period owing to rising awareness about allergic disorders and asthma among people especially children as well as adolescents coupled with growing disposable income levels in emerging countries such as China & India which will increase their demand for medicines that treat these conditions thereby driving this segment growth over next eight years.
Growth Factors:
- Increasing prevalence of allergic diseases: The increasing prevalence of allergic diseases is one of the major growth drivers for the C5a Anaphylatoxin Chemotactic Receptor 1 market. According to a study by the World Allergy Organization, approximately 300 million people suffer from asthma worldwide, and this number is expected to increase to 400 million by 2025. This will create a high demand for C5a Anaphylatoxin Chemotactic Receptor 1 products and services in the coming years.
- Rising awareness about anaphylaxis: Anaphylaxis is a potentially life-threatening condition that can occur when someone is exposed to an allergen. It can cause symptoms such as swelling of the throat, difficulty breathing, and loss of consciousness. There has been a rising awareness about anaphylaxis in recent years due to several high-profile cases in which people have died after being exposed to allergens such as peanuts or bee venom. This is likely to drive demand for C5a Anaphylatoxin Chemotactic Receptor 1 products and services in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
C5a Anaphylatoxin Chemotactic Receptor 1 Market Research Report
By Type
EP-67, NOXD-19, NOXD-20, DF-2593A, Others
By Application
Acute Pain, Allergic Asthma, Huntington Disease, Kidney Disease, Others
By Companies
AFFiRiS AG, ChemoCentryx, Inc., Dompe Farmaceutici S.p.A., Noxxon Pharma AG, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global C5a Anaphylatoxin Chemotactic Receptor 1 Market Report Segments:
The global C5a Anaphylatoxin Chemotactic Receptor 1 market is segmented on the basis of:
Types
EP-67, NOXD-19, NOXD-20, DF-2593A, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Pain, Allergic Asthma, Huntington Disease, Kidney Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AFFiRiS AG
- ChemoCentryx, Inc.
- Dompe Farmaceutici S.p.A.
- Noxxon Pharma AG
- ...
Highlights of The C5a Anaphylatoxin Chemotactic Receptor 1 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- EP-67
- NOXD-19
- NOXD-20
- DF-2593A
- Others
- By Application:
- Acute Pain
- Allergic Asthma
- Huntington Disease
- Kidney Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the C5a Anaphylatoxin Chemotactic Receptor 1 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
C5a anaphylatoxin chemotactic receptor 1 (C5aR1) is a protein that in humans is encoded by the C5AR1 gene. The C5aR1 protein functions as a receptor for the toxic compound ciclosporin, which binds to and activates this protein. This activation leads to the release of other mediators, including cytokines and prostaglandins, which can contribute to inflammation and allergic responses.
Some of the key players operating in the c5a anaphylatoxin chemotactic receptor 1 market are AFFiRiS AG, ChemoCentryx, Inc., Dompe Farmaceutici S.p.A., Noxxon Pharma AG.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. C5a Anaphylatoxin Chemotactic Receptor 1 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. C5a Anaphylatoxin Chemotactic Receptor 1 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. C5a Anaphylatoxin Chemotactic Receptor 1 Market - Supply Chain
4.5. Global C5a Anaphylatoxin Chemotactic Receptor 1 Market Forecast
4.5.1. C5a Anaphylatoxin Chemotactic Receptor 1 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. C5a Anaphylatoxin Chemotactic Receptor 1 Market Size (000 Units) and Y-o-Y Growth
4.5.3. C5a Anaphylatoxin Chemotactic Receptor 1 Market Absolute $ Opportunity
5. Global C5a Anaphylatoxin Chemotactic Receptor 1 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Type
5.3.1. EP-67
5.3.2. NOXD-19
5.3.3. NOXD-20
5.3.4. DF-2593A
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global C5a Anaphylatoxin Chemotactic Receptor 1 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Application
6.3.1. Acute Pain
6.3.2. Allergic Asthma
6.3.3. Huntington Disease
6.3.4. Kidney Disease
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global C5a Anaphylatoxin Chemotactic Receptor 1 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global C5a Anaphylatoxin Chemotactic Receptor 1 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global C5a Anaphylatoxin Chemotactic Receptor 1 Demand Share Forecast, 2019-2029
9. North America C5a Anaphylatoxin Chemotactic Receptor 1 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Application
9.4.1. Acute Pain
9.4.2. Allergic Asthma
9.4.3. Huntington Disease
9.4.4. Kidney Disease
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Type
9.7.1. EP-67
9.7.2. NOXD-19
9.7.3. NOXD-20
9.7.4. DF-2593A
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America C5a Anaphylatoxin Chemotactic Receptor 1 Demand Share Forecast, 2019-2029
10. Latin America C5a Anaphylatoxin Chemotactic Receptor 1 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Application
10.4.1. Acute Pain
10.4.2. Allergic Asthma
10.4.3. Huntington Disease
10.4.4. Kidney Disease
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Type
10.7.1. EP-67
10.7.2. NOXD-19
10.7.3. NOXD-20
10.7.4. DF-2593A
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America C5a Anaphylatoxin Chemotactic Receptor 1 Demand Share Forecast, 2019-2029
11. Europe C5a Anaphylatoxin Chemotactic Receptor 1 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Application
11.4.1. Acute Pain
11.4.2. Allergic Asthma
11.4.3. Huntington Disease
11.4.4. Kidney Disease
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Type
11.7.1. EP-67
11.7.2. NOXD-19
11.7.3. NOXD-20
11.7.4. DF-2593A
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe C5a Anaphylatoxin Chemotactic Receptor 1 Demand Share, 2019-2029
12. Asia Pacific C5a Anaphylatoxin Chemotactic Receptor 1 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Application
12.4.1. Acute Pain
12.4.2. Allergic Asthma
12.4.3. Huntington Disease
12.4.4. Kidney Disease
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Type
12.7.1. EP-67
12.7.2. NOXD-19
12.7.3. NOXD-20
12.7.4. DF-2593A
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific C5a Anaphylatoxin Chemotactic Receptor 1 Demand Share, 2019-2029
13. Middle East & Africa C5a Anaphylatoxin Chemotactic Receptor 1 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Application
13.4.1. Acute Pain
13.4.2. Allergic Asthma
13.4.3. Huntington Disease
13.4.4. Kidney Disease
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa C5a Anaphylatoxin Chemotactic Receptor 1 Market Size and Volume Forecast by Type
13.7.1. EP-67
13.7.2. NOXD-19
13.7.3. NOXD-20
13.7.4. DF-2593A
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa C5a Anaphylatoxin Chemotactic Receptor 1 Demand Share, 2019-2029
14. Competition Landscape
14.1. Global C5a Anaphylatoxin Chemotactic Receptor 1 Market: Market Share Analysis
14.2. C5a Anaphylatoxin Chemotactic Receptor 1 Distributors and Customers
14.3. C5a Anaphylatoxin Chemotactic Receptor 1 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AFFiRiS AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. ChemoCentryx, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Dompe Farmaceutici S.p.A.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Noxxon Pharma AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ...
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
